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Abstract 
Objective: Investigate pain sensitivity in women 
with vestibulodynia using two experimental pain 
assessments outside the vulvar region: 
intramuscular infusion of an acidic phosphate 
buffer and pressure pain thresholds (PPTs) of 
the lower limb.   
Methods: Three women with a history of 
vestibulodynia (all 24 years old) participated 
after providing written informed consent.  PPTs 
of the lower limb were assessed using a hand-
held Somedic digital algometer (30 kilopascal 
(kPa)/sec) at baseline (pre-infusion) and during 
the intramuscular infusion. The acidic phosphate 
buffer (pH 5.2) was infused into the anterior 
tibialis muscle at a rate of 40 ml/hr for 15 min 
(10 ml total).  Peak local (infusion site) and 
referred (ankle) pain ratings were assessed 
verbally, as well as vulvar pain at the time of the 
infusion (0 – 10 Borg Scale).   
Results: Peak local pain was higher in two of the 
three subjects (2.5, 4.0, 9.5) than the average 
pain ratings in 34 healthy age-matched (21 – 27 
years old) women from our laboratory, mean 
3.0/10 (standard deviation (SD) 2.2; range 0.5 to 
10). Peak referred pain was also higher in the 
same two subjects (0, 4.25, and 7.5) than the 
average of the controls (mean 1.5; SD 1.8; 
range 0 – 9.0).  Similarly, vulvar pain patients all 
exhibited greater mechanical pain sensitivity 
(lower PPT values) than the average of the 
healthy controls (mean [SD] 246.3 [101.7] kPa in 
patients vs. 431.3 [109.33] in controls).  
Conclusion: Preliminary data suggests women 
with vestibulodynia may exhibit greater 
generalized pain sensitivity to noxious stimuli 
than the general population of women.   
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Introduction 
Pain in the United States is an 
enormous problem that leads to 
impairment and disability, resulting in 
social and economic consequences for 
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both the individual and society. Thirty-
four million Americans suffer from 
chronic pain. The cost for relief for back 
pain, migraines, and arthritis alone 
exceeds $40 billion annually.1 Pain is 
cited as the primary reason for 50 
million work days lost per year.1 
Pain is highly multidimensional, leading 
to differing sensations depending on 
origins from musculoskeletal tissue, soft 
tissue, or cutaneous regions.2 Human 
pain perception varies greatly between 
individuals and results from the 
integration of unique objective, sensory, 
cognitive, and affective processes.3 
Other contributing factors to the 
experience of pain are central and 
peripheral sensitization.4 Central 
sensitization refers to enhanced neural 
responsiveness within the dorsal horn of 
the spinal cord and prolonged C fiber 
activity. Peripheral sensitization refers to 
the lowered nociceptor threshold for 
stimulation. There are growing interests 
to better understand the individual 
differences in central and peripheral 
contributions to pain perception and 
tolerance, ultimately to lessen the 
burden of pain management. 
Experimental pain provides the unique 
opportunity to investigate pain sensitivity 
through the use of controlled noxious 
stimuli.  Methods to induce experimental 
pain are categorized as endogenous 
and exogenous.6 Endogenous methods 
involve activating pain without the 
exposure of an external substance, such 
as isometric or eccentric exercises to 
induce tissue hypoxia. Exogenous 
methods involve the use of external 
stimuli, such as electrical or chemical 
stimulation of nociceptors.6 Hypertonic 
saline and acidic saline injections are 
exogenous models used to produce 
temporary myalgias, with no adverse 
side effects reported over thousands of 
infusions, suggesting technique safety.7 
Frey Law, et al., studied central 
sensitization using an acidic buffer 
infusion (pH 5.2) and found that muscle 
acidosis produced light to moderate, 
and rate-dependent, muscular pain at 
the site of infusion as well as referred 
pain in a distant site compared to control 
infusions.8 Sluka, et al., also found that 
an acidic infusion into muscular tissue 
can produce hyperalgesia in animal 
models, with maximum activation of 
nociceptors occurring at a pH of 5.2, 
and consistent activation at a pH of 6.0.9 
Thus, an acidic infusion pain model can 
be used to examine both local and 
referred pain safely in humans. 
Vulvodynia is a chronic pain disorder 
characterized by increased sensitivity of 
external stimuli at the vulva and/or 
spontaneous vulvar pain in the absence 
of disease pathology.10-13 The pain is 
often described as knife like, burning, 
irritation or itching, and can be provoked 
or unprovoked.10, 11 Lifetime prevalence 
of vulvodynia is 10-15% in the United 
States and cost of care in the USA has 
been cited as being greater than $8000 
per patient for a 6 month course of 
treatment.13 Vulvodynia is thought to be 
augmented by central sensitization, as 
evidenced by dynamic vulvar tactile 
allodynia, body-wide pain threshold 
reductions, and pain hypervigilance and 
anxiety.14 Hampson, et al., further 
clarified this hypothesis, by showing that 
women with vulvodynia also experience 
increased pain perception at peripheral 
tissues such as the thumb, deltoid, and 
shin, suggesting that factors remote 
from the vulva may play a role in 
symptom perception.12  
Proceedings in Obstetrics and Gynecology, 2017;7(1):3 
Pain sensitivity and vestibulodynia  3 
 
This study aims to investigate pain 
sensitivity with vestibulodynia using two 
experimental pain assessments of the 
lower limb: intramuscular infusion of an 
acidic phosphate buffer to examine local 
and referred pain, and pressure pain 
thresholds before and during the 
infusion.  
Methods 
Subjects 
Three women with a history of 
vestibulodynia, all aged 24 years, 
participated in this pilot study after 
providing written informed consent as 
approved by the local Institutional 
Review Board. Exclusion criteria 
included history of cardiovascular, 
neuromuscular diseases, history of 
diabetes/neuropathy or other 
immunocompromise, other current 
chronic pain besides vulvodynia, 
pregnancy, significant injury to lower 
extremities, and inability to 
communicate. Participants were 
compared to 34 age-matched (21-27 yr.) 
and sex matched controls. Exclusion 
criteria for control participants included 
current pain complaints, past history of 
chronic pain, significant medical history, 
prescription medications other than birth 
control or vitamins, pregnancy, and 
history of lower extremity injury. 
Participants were instructed that 
moderate muscle pain could occur and 
were reimbursed for their time (1.5 hr 
per visit).  
Study protocol 
Subjects participated in two visits, 
spaced 5-14 days apart. An acidic 
phosphate buffer was infused into the 
anterior tibialis muscle at a rate of 40 
ml/hr for 15 min, for a total of 10 ml. 
While hypertonic saline has been used 
in patient populations (e.g. elbow 
tendinitis, fibromyalgia, osteoarthritis) 
this acidic phosphate infusion has not. It 
is not used as treatment, but as an 
experimental model to investigate the 
pain responses elicited by this noxious 
stimulus. The advantage of acid over 
hypertonic saline is that it may be more 
physiologically appropriate (activates 
ASICs and TRPV1 channels) which are 
specific to pain nociceptors as opposed 
to sodium channels which are not 
specific to pain. Further, this acidic 
phosphate buffer provides a means that 
has been repeatedly shown to induce 
referred pain in about 60% of the 
population (higher in women), and may 
be useful for examining this centrally 
mediated phenomenon in patient 
populations more specifically. 
The acidic buffer was prepared by the 
local hospital pharmacy with a pH of 5.2 
in sterile 30 mL syringes, and was iso-
osmotic to saline. Peak local (infusion 
site) and referred (ankle) pain ratings 
were assessed verbally before, during, 
and 20 minutes after infusion, as well as 
any vulvar pain at the time of the 
infusion. Pressure pain thresholds 
(PPTs) of the lower limb were assessed 
as the average of multiple repetitions 
using a digital hand-held Somedic digital 
algometer (30 kPa/sec, 1 cm2 tip) at 
baseline (pre-infusion, n=4 repetitions) 
and during the intramuscular infusion 
(n=2 each assessment) (Figure 1). 
Baseline algometer repetitions were 
done before and after the insertion of 
the catheter (2 each) and were found to 
be the same. Thus, the protocol was 
collapsed to a single baseline of 4 
repetitions. Participants were instructed 
Proceedings in Obstetrics and Gynecology, 2017;7(1):3 
Pain sensitivity and vestibulodynia  4 
 
to press the hand-held trigger when the 
pressure first became painful (i.e., “a 1 
out of 10”). PPTs were determined at 
four locations ipsilateral to the infusion 
(upper and lower anterior tibialis, 
anterior ankle, and web space between 
1st and 2nd metatarsals on the foot) and 
two mirrored contralateral locations 
(lower anterior tibialis and ankle). Radial 
artery pulse at the wrist was measured 
manually every 5 minutes throughout 
the 45 minute protocol. For more 
information on study protocol and 
specifics of intramuscular infusions, see 
Frey Law, et al.8  
Descriptive statistics (mean, standard 
error of the mean (SEM)) were 
calculated for all pain and sensory 
variables.  
Z-scores and percentile ranks for the 
pain responses were calculated for each 
patient using the healthy control mean 
and variance data. 
 
 
Figure 1: A patient undergoing acidic phosphate buffer (pH 5.4) infusion and 
measurement of pressure pain thresholds (PPTs).  
 
Results 
All participants completed the study. No 
complications occurred during the study 
and heart rate did not vary during any of 
the infusions. Patient 1 reported resting 
vulvar pain at the time of the study (2/10 
rating), while Patients 2 and 3 had zero 
pain prior to the infusion.  
Experimental pain responses are 
provided in Table 1. Pain was zero prior 
to starting the infusion; pain ratings are 
reported as the difference/ change from 
baseline. Patient 1 had no referred pain 
and a lower peak local pain rating (2.5) 
than healthy controls, placing her below 
average (20th and 33rd percentiles, 
respectively) relative to healthy women. 
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However, peak local pain was higher in 
Patients 2 and 3 (9.5 and 4.0, 
respectively) than the average observed 
in the 34 controls, placing them above 
99 and 68 percent of healthy women, 
respectively, for this local pain 
response. Peak referred pain was also 
higher in the same two subjects (7.5 and 
4.25, respectively) than the average of 
the healthy age- and sex-matched 
controls, resulting in 100th and 94th 
percentile ranks. Similarly, the vulvar 
pain patients all exhibited greater 
mechanical pain sensitivity as 
evidenced by lower average PPT values 
than the average of the healthy controls, 
with percentile ranks from 79th to 100th. 
Table 1. Absolute and percentile pain responses for each individual patient and 
means (SD) for healthy controls. 
 Patient 1 Patient 2 Patient 3 Healthy Controls (N=34) 
Resting Vulvar pain 2 0 0 - 
Local Infusion Pain (0 – 10 scale) 2.5 9.5 4.0 3.0 (2.2) 
    percentile 32.5% 99.8% 67.5% - 
Referred pain (ankle, 0- 10) 0 7.5 4.25 1.5 (1.8) 
    percentile 20.2% 99.9% 93.7% - 
PPTs (kPa) 225 140 343 431 (109) 
    percentile 97.0% 99.6% 79.0%  
* PPT = pressure pain threshold at 30 kPa/sec, 1 cm2 tip (average of all locations). 
  
Discussion 
This is one of the first studies to 
examine exogenous pain model 
sensitivity in this patient population. We 
found in two of three patients, higher 
than average local and referred pain 
sensitivity, as well as elevated pressure 
pain sensitivity (lowered thresholds) in 
all three patients relative to healthy age- 
and sex-matched controls. The findings 
of decreased pressure pain thresholds 
in all of the subjects with vestibulodynia 
support the theory that women with 
vestibulodynia may exhibit greater 
generalized pain sensitivity to noxious 
stimuli than the general population of 
women. Further the large range in 
experimental pain responses observed 
in only three patients, suggests the 
potential for substantial heterogeneity in 
pain processing in this patient 
population.  
While this is a small pilot investigation 
that cannot be generalized to the 
population as a whole, this data is 
congruent with other studies on this 
topic, suggesting that peripheral and 
central nervous system sensitization is 
likely involved in the initiation or 
maintenance of this chronic pain 
condition. Reed, et al., assessed 
differences in vulvar and peripheral 
sensitivity and similarly found women 
with vulvodynia were more sensitive to 
pressure and electrical stimuli than were 
control women at the vulva and at the 
thumb.15 Foster, et al., compared the 
response to intradermal capsaicin at the 
forearm and foot of women with 
vestibulodynia to controls, and found 
that patients with vestibulodynia 
demonstrated altered pain processing 
extending to regions far beyond the 
vulva.4 Hampson, et al., found 
augmented brain activation on fMRI 
studies in women with vulvodynia 
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compared to controls during local and 
remote (thumb) pressure evoked pain.12 
These alterations in pain sensitivity were 
more analogous to irritable bowel 
syndrome and fibromyalgia syndrome 
than to site-specific pain perceptions 
found in, for example, post herpetic 
neuralgia or rheumatoid arthritis, 
consistent with central sensitization.4,12  
Interestingly, resting vulvar pain was not 
predictive of greater pain sensitivity or 
referred pain to the ankle, as evidenced 
by Patient 1. One theory to explain this 
is the involvement of descending 
inhibitory pain pathways during a period 
of baseline vulvar pain. That is, the “pain 
inhibits pain” phenomenon or 
conditioned pain modulation, where pain 
activates descending inhibitory 
pathways. These pathways arise in 
multiple areas of the cerebrum and 
brainstem and inhibit transmission of 
nociceptive inputs at the level of the 
dorsal horn.16 Obviously, it is difficult to 
draw conclusions with a sample size of 
one and this patient could very well be 
an outlier, or simply be evidence that 
baseline pain is not predictive of evoked 
pain sensitivity.  
Our findings of increased pressure pain 
thresholds outside the vulva region and 
referred pain, a form of central 
sensitization, in this small pilot study 
may further suggest the involvement of 
centrally-mediated pain mechanisms.  
This supports the hypothesis that 
treatment may be more efficacious if 
targeted to systemic rather than local 
therapies as well as using combination 
therapies to act on two or more pain 
pathways (peripheral sensitization, 
central sensitization, and pain inhibitory 
pathways). Continued research is 
needed to examine the underlying 
mechanisms of vestibulodynia and 
develop new therapies to augment the 
options in current use. 
This study was IRB approved by the University 
of Iowa. 
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